Remogliflozin etabonate
Remogliflozin etabonate is a prodrug metabolized to the active SGLT2 inhibitor remogliflozin. It shows high selectivity for inhibiting SGLT2 over SGLT1, as evidenced by its Ki values against human and rat isoforms. This compound is utilized in preclinical research to investigate SGLT2 function in diabetes and metabolic disease models.
Product Specifications
CAS Number
442201-24-3
Product Name Alternative
GSK189075, GSK-189075, GSK189075A, GSK-189075A, GSK 189075, GSK 189075A, Remogliflozin etabonate, SGLT2
Field of Research
Pharmacology & Drug Discovery
Purity
98.98% (May vary between batches)
Solubility
DMSO:90 mg/mL (172.22 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.31 mM)
Smiles
CCOC (=O) OC[C@H]1O[C@@H] (Oc2nn (C (C) C) c (C) c2Cc2ccc (OC (C) C) cc2) [C@H] (O) [C@@H] (O) [C@@H]1O
Molecular Formula
C26H38N2O9
Molecular Weight
522.59
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ALG13, ID (ALG13, CXorf45, UDP-N-acetylglucosamine transferase subunit ALG13 homolog, Asparagine-linked glycosylation 13 homolog, Glycosyltransferase 28 domain-containing protein 1)
PBX1 (pre-B-Cell Leukemia Homeobox 1, DKFZp686B09108, MGC126627) (MaxLight 550)
